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Abstract
Background: Dysregulation of the hypothalamic-pituitary-adrenal (HPA) axis is thought to be associated with more mood
symptoms and worse cognitive functioning. This study examined whether variation in HPA axis activity underlies the
association between mood symptoms and cognitive functioning.
Methodology/Principal Findings: In 65 bipolar patients cognitive functioning was measured in domains of psychomotor
speed, speed of information processing, attentional switching, verbal memory, visual memory, executive functioning and an
overall mean score. Severity of depression was assessed by the Inventory of Depressive Symptomatology-self rating version.
Saliva cortisol measurements were performed to calculate HPA axis indicators: cortisol awakening response, diurnal slope,
the evening cortisol level and the cortisol suppression on the dexamethasone suppression test. Regression analyses of
depressive symptoms and cognitive functioning on each HPA axis indicator were performed. In addition we calculated
percentages explanation of the association between depressive symptoms and cognition by HPA axis indicators. Depressive
symptoms were associated with dysfunction in psychomotor speed, attentional switching and the mean score, as well as
with attenuation in diurnal slope value. No association was found between HPA axis activity and cognitive functioning and
HPA axis activity did not explain the associations between depressive symptoms and cognition.
Conclusions/Significance: As our study is the first one in this field specific for bipolar patients and changes in HPA-axis
activity did not seem to explain the association between severity of depressive symptoms and cognitive functioning in
bipolar patients, future studies are needed to evaluate other factors that might explain this relationship.
Citation: van der Werf-Eldering MJ, Riemersma-van der Lek RF, Burger H, Holthausen EAE, Aleman A, et al. (2012) Can Variation in Hypothalamic-Pituitary-Adrenal
(HPA)-Axis Activity Explain the Relationship between Depression and Cognition in Bipolar Patients? PLoS ONE 7(5): e37119. doi:10.1371/journal.pone.0037119
Editor: Xiang Yang Zhang, Baylor College of Medicine, United States of America
Received January 30, 2012; Accepted April 18, 2012; Published May 14, 2012
Copyright:  2012 van der Werf-Eldering et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which
permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: MWE has received a Young Investigator’s award from AstraZeneca, The Netherlands and a Lilly Travel Fellowship for 9th International Conference on
Bipolar Disorder. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have read the journal’s policy and have the following conflicts. W.A. Nolen has received grants from the Netherlands
Organization for Health Research and Development, the European Union, the Stanley Medical Research Institute, Astra Zeneca, Eli Lilly, GlaxoSmithKline and
Wyeth; W.A. Nolen has received honoraria/speaker’s fees from Astra Zeneca, Pfizer, Servier and Wyeth and has served in advisory boards for Astra Zeneca, Pfizer
and Servier. R.F. Riemersma-van der Lek has received speaker’s fees from Astra Zeneca. A. Aleman received an investigator-initiated unrestricted research grant
from Brystol-Myers Squibb and speakers bureau honoraria from AstraZeneca, Brystol-Myers Squibb, GlaxoSmithKline and Janssen. This does not alter the authors’
adherence to all the PLoS ONE policies on sharing data and materials. The other authors deny any conflicts of interest or commercial associations in connection
with the submitted manuscript.
* E-mail: m.j.van.der.werf@umcg.nl
Introduction
Bipolar disorder is characterized by recurrent (hypo)manic and
depressive mood episodes. Moreover, many, but not all bipolar
patients show cognitive dysfunction in areas of attention, memory
and executive functioning, not only during mood episodes [1,2]
but also when euthymic [3,4] possibly indicating trait-like
expressions of a genetic phenotype. However, cognitive dysfunc-
tion may be more pronounced during depressive episodes [1,2].
Dysregulation of the hypothalamic-pituitary-adrenal (HPA) axis
has been suggested to be involved [5–7]. For many years a change
in set point of the HPA system, resulting in altered regulation of
cortisol secretory activity [ultimately expressed as hypercortisolism
and impaired glucocorticoid receptor function; [8]] has been
emphasized in (unipolar) depression [9–11] as well as bipolar
disorder [12–14]. Moreover, patients with more severe illness
characteristics, such as longer duration of illness and higher
number of episodes, as well as psychotic features, appear to show
even worse HPA dysregulations [13–16].
All these characteristics are difficult to disentangle, but they are
considered relevant in the pathogenesis and pathophysiology of
bipolar disorders; endocrine abnormalities are thought to lead not
only to affective symptoms, but also to contribute to cognitive
problems due to partly reversible structural changes in the brain
[7,13,17]. Patient and illness characteristics such as age and
severity of the illness have been suggested as determinants of these
problems. Although the underlying mechanism is essentially
PLoS ONE | www.plosone.org 1 May 2012 | Volume 7 | Issue 5 | e37119unknown, dysregulation of the HPA-axis is thought to be involved.
Although the precise time course remains unclear, fast and
reversible negative effects of cortisol on cognition have been
demonstrated in animal and human model studies [18]. Studies in
healthy younger [19] and older [20] populations suggested that
psychosocial stress and subsequent cortisol excess is one of the
mechanisms underlying (reversible) cognitive dysfunction. Re-
garding depression, many studies indicated an important role for
HPA axis hyperactivity (including the use of corticosteroids) in its
pathophysiology, affecting cognition through different neuronal
networks [6,7,13,15,17,21,22]. Consequently, HPA axis hyperac-
tivity has been the focus of novel therapeutic approaches targeting
the HPA axis in order to improve not only mood symptoms, but
also cognitive functioning [6,15,17].
The first studies to disentangle the association between mood
symptoms, HPA responses and cognitive functioning have shown
different results. Reppermund et al. [23] studied 75 inpatients with
major depressive disorder and revealed that slowed speed of
information processing measured by averaging the time of two
matrices of the Zahlenverbindungstest was associated with more
mood symptoms, whereas improvement of verbal short term
memory was associated with decreased cortisol response, which
was evaluated with the dexamethasone (DEX)/corticotropin-
releasing hormone (CRH) test. Egeland et al. [24] studied 26
patients with major depressive disorder and found that impair-
ments in executive functioning and memory retrieval, both typical
for depressive patients, were related to morning cortisol levels,
whereas psychomotor retardation was associated with severity of
mood symptoms. Zobel et al. [25] studied 64 patients with major
depressive disorder and described an improvement of working
memory instead of depressive symptoms after normalization of
cortisol response pattern in the DEX/CRH test; no relationship
was found between episodic memory and cortisol.
Aim of the study
The interplay between mood symptoms and HPA axis activity
in their relation with cognitive functioning in bipolar patients is
unclear. The present study is, to the best of our knowledge, the first
to investigate the HPA axis as a factor explaining the association
between depressive symptoms and cognitive functioning in bipolar
disorder. Based on the sparse literature as described above, we
expected to find an increased HPA axis activity in patients with
cognitive dysfunction. As we have found in a previous study that
cognitive functioning was associated with depressive symptoms
[26], we hypothesized that HPA axis activity might explain this
association.
Materials and Methods
Ethics Statement
The procedures were approved by the institutional review board
of the University Medical Center Groningen (reference numbers
METc2005.236 and METc2007.200), and in accordance with the
latest version of the Declaration of Helsinki. All participants had
the capacity to consent, since strict inclusion and exclusion criteria
were followed with regard to patient characteristics which could be
able leading to reduced capacity to consent (e.g. excluding those
patients suffering from severe depressive symptoms and/or
(hypo)manic symptoms or patients with IQ,70; for further details
see section 2.2). All participants gave written informed consent
after the nature of the procedures had been fully explained.
Participants
The current study was part of a larger study in bipolar patients
we performed between October 2005 and December 2008 in
which we explored the kind and extent of cognitive functioning as
well as the association with depressive symptoms [26]. All patients
(age 18–65 years) had DSM-IV bipolar I or II disorder, confirmed
by the Mini-International Neuropsychiatric Interview (MINI;
[27]). Mild to moderate depressive symptoms were allowed,
defined as a score of #38 points [28,29] on the 30 item-Inventory
of Depressive Symptomatology-self rating (IDS-SR; [30]). Hypo-
manic or manic symptoms were not allowed, defined as .7 points
on the Young Mania Rating Scale (YMRS; [31]). Other exclusion
criteria were: mental retardation (IQ,70), a known systemic or
neurological disease which could influence cognitive functioning,
endocrine disorders, the use of corticosteroids and the need for
current treatment for substance use disorders in a specialized
setting.
All patients who took part in the larger study were asked to
participate in the current study which implied saliva sampling
within 4 weeks after completion of the cognitive tests. Additional
exclusion criteria were: current pregnancy, current breastfeeding,
current use of corticosteroids or a delay of more than 30 days
between cognitive testing and cortisol sampling. Due to refusal to
take part in this additional study (n=30, 27.3%), the use of
corticosteroids (n=2, 1.8%), missing saliva data (n=6, 5.5%) and
delay of more than 30 days of saliva sampling (n=7, 6.4%), 65 out
Table 1. Data of 14 cognitive outcome variables, summarized
in 6 domains (bold) for 65 bipolar patients.
Raw data
Mean SD
Psychomotor speed
Simple movement time (msec) 450.06 133.77
Five-choice movement time (msec) 409.45 109.24
Speed of information processing
Simple reaction time (msec) 349.64 95.33
Five-choice reaction time (msec) 383.65 103.94
Stroop time 1 (word; sec) 44.49 8.67
Stroop time 2 (color; sec) 57.74 12.84
Attentional switching
Difference CPT hitrate version Q minus HQ 0.05 0.07
- CPT hitrate version Q (% correct) 0.996 0.01
- CPT hitrate version HQ (% correct) 0.947 0.07
Verbal memory
CVLT – verbal learning (total nr correct resp)
$ 53.94 12.09
CVLT – long term free recall (nr correct resp)
$ 12.25 3.18
Visual memory
PRM – number correct immediate
$ 10.57 1.54
PRM – number correct delayed
$ 9.34 1.85
Executive functioning/working memory
SWM – between errors 8 boxes (nr correct resp) 23.46 12.23
SWM – strategy (efficiency score) 35.37 5.22
Stroop interference (difference rate; sec) 7.22 22.14
$higher score indicates better performance; in further analyses age-adjusted
data were reversed (100 minus score).
CPT: Continuous Performance Task; CVLT: Dutch version of California Verbal
Learning Test; PRM: Pattern Recognition Memory; SWM: Spatial Working
Memory; msec: milliseconds; sec: seconds; nr: number; resp: responses.
doi:10.1371/journal.pone.0037119.t001
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Non-participants did not differ from the final bipolar sample in age
(t=21.39, p=0.17), education level (t=20.41, p=0.69), gender
(x
2=3.44, p=0.06) or subtype of bipolar disorder (x
2=0.75,
p=0.69).
Measurements
Measurementsofcharacteristicsandsymptoms. Clinical
evaluation tookplace duringthe phase of cognitive testing. Patients’
and lifetime illness characteristics were provided by the clinician via
the Questionnaire for Bipolar Disorder (BP; an adaption of the
Enrollment Questionnaire as previously used in the Stanley
Foundation Bipolar Network; [32,33]). In case of mismatch of
results from the MINI in relation to the QBP, diagnoses were
checked with the treating clinician. The level of depressive
symptoms was measured by the 30 item-Inventory of Depressive
Symptomatology-self rating [IDS-SR; [30]]. The level of education
was based on the Dutch educational system which differentiates
already after primary school into different levels, ranging from 1:
primary school up to 6: PhD student or higher degree.
Neurocognitive assessment. The cognitive test battery has
been described elsewhere [26]. In short, the composition of the
cognitive test battery was based on existing literature and
experience with the target group in clinical practice. The battery
included six cognitive domains (psychomotor speed, speed of
information processing, attentional switching, verbal memory,
visual memory and executive functioning/working memory),
consisting of seven different tests, yielding 14 outcome variables
(see Table 1). In addition, premorbid intelligence (IQ) was
estimated with the National Adult Reading Test (NART; [34]).
Detailed descriptions of the pen-and-paper measures are provided
by Lezak et al. [35]. Robbins et al. [36] discussed the tests from the
Cambridge Neuropsychological Test Automated Battery, a com-
puter-based cognitive assessment system which can be adminis-
tered to subjects using a touch screen computer to examine various
areas of cognitive function. The total cognitive test battery was
administered within about 2K hours, with one break if necessary.
Table 2. Characteristics for the 65 bipolar patients.
Mean SD
Age (years) 46.9 10.4
Premorbid IQ 107.5 9.3
Education level (range 1–6) 3.6 1.0
Duration of illness (years) 21.8 13.1
IDS-SR 17.0 10.7
YMRS 0.35 1.1
Cortisol (mmol/dL)
- T1, at awakening 16.8 6.8
- T2, 30 min after awakening (n=63) 18.8 8.4
- T3, 45 min after awakening (n=61) 19.5 10.8
- T4, 60 min after awakening (n=62) 18.4 12.8
- AUCg (n=61) 18.4 7.5
- AUCi (n=61) 1.8 7.0
- T5, at 10 PM (n=59) 4.4 2.7
- T6, at 11 PM (n=62) 5.2 4.6
- mean evening cortisol (n=58) 4.8 3.1
- diurnal slope decline per hour (n=62) 0.7 0.6
- T7, at awakening (n=56) 7.3 3.7
- DST suppression ratio (n=56) 3.1 2.7
N%
Female gender 44 67.7
Bipolar disorder type I 53 81.5
Type of medication
- Lithium 43 66.2
- Anticonvulsants
{ 26 40.0
- Antipsychotics 15 23.1
- Antidepressants 10 15.4
- Benzodiazepines 5 7.7
- None 2 3.1
{1 patient used two different types of anticonvulsants.
AUCg: area under the curve (AUC) with respect to the ground; AUCi: AUC with respect to the increase; DST: cortisol suppression on the dexamethasone suppression
test; IDS-SR: Inventory of Depressive Symptomatology-self rating; YMRS: Young Mania Rating Scale.
doi:10.1371/journal.pone.0037119.t002
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according to procedures of the Netherlands Study of Depression
and Anxiety (NESDA; [11,37]). Salivary sampling has shown to be
a reliable and minimally intrusive method to assess the active,
unbound form of cortisol [38]. Patients were instructed to collect
saliva samples at a day with regular activities (not a resting day,
e.g. weekend or holiday) as soon as possible after the cognitive
testing day. The median time between the cognitive testing day
and saliva sampling was 6.0 days (25
th–75
th percentile, 2.0–11.5
days). Together with the saliva samples patients filled out
a questionnaire, which described the time of awakening and
subsequent saliva sampling times with the first one at awakening
(T1), 30 (T2), 45 (T3) and 60 (T4) minutes after awakening and
evening levels at 10 pm (T5) and 11 pm (T6).
Also in accordance with NESDA [11,37], four cortisol
indicators were used in this study: cortisol awakening response
(CAR), evening cortisol level, diurnal slope, and cortisol suppres-
sion after the administration of 0.5 mg dexamethasone at 2300 h
(T6; dexamethasone suppression test; DST). The CAR included
four sampling points: at awakening (T1) and at 30 (T2), 45 (T3)
and 60 (T4) minutes later. The CAR was assessed by calculating
the area under the curve (AUC) with respect to the ground
(AUCg) and with respect to the increase (AUCi), conform the
formulas by Pruessner et al. [39]. Only the AUCg was used for
further analysis as the AUCi was in 25 cases negative due to the
fact that T1 was higher than the subsequent values after
awakening. Values were assigned missing in case of sampling
outside a margin of 5 minutes before or after the time protocol or
in case of more than 2 SDs from the mean. For AUC analyses, at
least 3 samples had to be available. In 10 cases the missing value
was imputed using linear regression analyses including information
on the available 3 cortisol levels, sex, age and awakening time.
Evening cortisol levels were collected at 10 pm (T5) and 11 pm
(T6). The mean of the two evening levels (T5 and T6) was used for
further analyses of evening cortisol, since both values were
moderately correlated (Pearson R=0.41, p=0.002). Diurnal slope
was calculated by subtracting the value at 2300 h (T6) from the
value at awakening (T1) and dividing it by the number of hours in
Table 3. Associations between depressive symptoms and cognitive performance, presented in subgroups of availability of the
respective HPA indicator.
CAR (n=61) Evening (n=58) Diurnal (n=62) DST (n=56)
Beta
{ [95%CI] Beta
{ [95%CI] Beta
{ [95%CI] Beta
{ [95%CI]
Speed 0.45 [0.12; 0.78] 0.50 [0.17; 0.83] 0.47 [0.14; 0.79] 0.47[0.16; 0.78]
Process 0.35 [20.01; 0.70] 0.26 [20.11; 0.63] 0.26 [20.10; 0.61] 0.29 [20.06; 0.65]
Attention 0.28 [0.05; 0.51] 0.25 [0.01; 0.48] 0.26 [0.04; 0.49] 0.02 [0.06; 0.53]
Verbal 0.003 [20.32; 0.33] 0.02 [20.29; 0.34] 0.08 [20.24; 0.40] 0.03 [20.30; 0.36]
Visual 0.10 [20.17; 0.36] 0.13 [20.13; 0.40] 0.14 [20.12; 0.40] 0.09 [20.17; 0.34]
Exec/WM 0.02 [20.26; 0.30] 0.02 [20.26; 0.31] 0.03 [20.24; 0.29] 20.01 [20.29; 0.27]
Mean 0.20 [0.03; 0.36] 0.20 [0.02; 0.37] 0.21 [0.04; 0.37] 0.19 [0.03; 0.36]
{All values are regression coefficients (beta’s) indicating the mean change in z-score of cognitive performance, associated with an increase of 13 points IDS-SR score.
Higher values indicate worse performance.
Betas are corrected for age, gender, education and IQ.
Speed=psychomotor speed; Process=speed of information processing; Attention=attentional switching; Verbal=verbal memory; Visual=visual memory; Exec/
WM=executive functioning/working memory; Mean=mean z-score of all 6 cognitive domains; CAR=cortisol awakening response; evening=mean evening cortisol
level; Diurnal=diurnal slope; DST=cortisol suppression on the dexamethasone suppression test; 95%CI=95% confidence interval.
doi:10.1371/journal.pone.0037119.t003
Table 4. Associations between HPA categories and cognitive performance.
CAR (n=61) Evening (n=58) Diurnal (n=62) DST (n=56)
Beta
{ [95%CI] Beta
{ [95%CI] Beta
{ [95%CI] Beta
{ [95%CI]
Speed 20.03 [20.06; 0.01] 0.03 [20.07; 0.12] 0.03 [20.47; 0.53] 0.09 [20.01; 0.19]
Process 0.01 [20.03; 0.05] 0.01 [20.09; 0.11] 0.09 [20.43; 0.60] 0.06 [20.05; 0.18]
Attention 0.02 [20.01; 0.04] 20.01 [20.08; 0.05] 20.05 [20.39; 0.29] 0.05 [20.02; 0.13]
Verbal 20.01 [20.05; 0.02] 20.03 [20.11; 0.05] 20.39 [20.83; 0.06] 20.04 [20.14; 0.06]
Visual 0.02 [20.01; 0.05] 0.004 [20.07; 0.07] 0.08 [20.29; 0.46] 20.01 [20.09; 0.08]
Exec/WM 0.02 [20.01; 0.05] 0.01 [20.06; 0.09] 20.28 [20.66; 0.10] 0.03 [20.06; 0.11]
Mean 0.003 [20.02; 0.02] 0.001 [20.05; 0.05] 20.09 [20.34; 0.16] 0.03 [20.02; 0.09]
{All values are regression coefficients (beta’s) indicating the mean change in cognitive performance, associated with an increase of 1 unit HPA value.
Higher values indicate worse performance.
Betas are corrected for age, gender, education and IQ.
Speed=psychomotor speed; Process=speed of information processing; Attention=attentional switching; Verbal=verbal memory; Visual=visual memory; Exec/
WM=executive functioning/working memory; Mean=mean z-score of all 6 cognitive domains; CAR=cortisol awakening response; evening=mean evening cortisol
level; Diurnal=diurnal slope; DST=cortisol suppression on the dexamethasone suppression test; 95%CI=95% confidence interval.
doi:10.1371/journal.pone.0037119.t004
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per hour [40]. The cortisol suppression ratio in the DST was
calculated by dividing the cortisol value at awakening on the first
day (T1) by the cortisol value at awakening the next morning (T7)
by strict instructions after the patients had taken the dexameth-
asone. The sample of the current analyses consisted of 61 out of 65
(93.8%) patients for CAR-analyses, 58 (89.2%) patients for evening
cortisol-analyses, 62 (95.4%) patients for diurnal slope-analyses
and 56 (86.2%) patient for DST-analyses. Comparing the cortisol
values with previous studies regarding unipolar and bipolar
depressed patients versus control groups, the cortisol data in this
study are in the same range [11,14].
Statistical analyses
Cognitive test scores were obtained in a previous study in which
we included 110 bipolar patients [26]. In line with this study
cognitive scores were transformed into age-adjusted z-scores using
the mean and standard deviations of 75 healthy controls. Higher
scores indicated worse performance. Cognitive domain scores
were created by calculating the mean z-value of the pertaining
cognitive variables. In addition, a mean score was created by
averaging the z-scores of all six domains.
The association of depressive symptoms with cognitive func-
tioning was quantified by performing linear regression analyses
with the age-corrected z-scores for cognition as the dependent
variable, and the IDS-SR total score and potential confounders for
this association gender, education and IQ as independent
variables. The continuous IDS-SR total score was divided by 13
and consequently the beta’s reported are per 13 points on the IDS-
SR. The choice of 13 points is essentially arbitrary but
approximately corresponds to continuously shifting from the level
of none (0–13) to mild (14–25) or from mild to moderate (25–38)
depressive symptoms, irrespective of the starting level of depressive
symptoms [28,29].
The associations of HPA axis activity indicators with cognitive
functioning and depressive symptoms were performed using the
same approach. In these analyses, higher scores of the HPA
indicators meant worse functioning, indicating a higher rate of
HPA axis dysregulation.
The last step was to investigate the potential explanation of the
associations between depressive symptoms and cognitive function-
ing by HPA-axis functioning. The amount of explanation was
defined as the change in the magnitude of the relation between
depressive symptoms and cognitive functioning when including the
HPA axis indicator as an independent variable. It was scaled as the
relative change in the regression coefficient for the HPA indicator
and was expressed as a percentage. We applied bootstrapping
techniques drawing 5000 samples with replacement to obtain 95%
confidence intervals (95%CI) for the percentages explained [41].
The analyses of percentage explained were restricted to those
cognitive domains shown to be significantly related to depressive
symptoms in our prior study [26] and to those HPA axis indicators
showing a statistically significant association with depressive
symptoms or with cognitive performance. The linear regression
model assumptions of normality, linearity and homoscedasticity
were assessed using residual plots and were found to be sufficiently
met in all analyses.
The level of statistical significance was set at 0.05, two-sided.
Analyses were performed using SPSS Version 16.0 [42].
Results
Sample characteristics
Raw neurocognitive data are presented in Table 1. De-
mographic and clinical characteristics of the bipolar sample are
listed in Table 2. The study included 53 bipolar I patients (81.5%)
and 12 bipolar II patients (18.5%). Patients were euthymic [n=29;
IDS-SR score ,14 [28,29]], mildly depressed [n=19; IDS-SR
score 14–25 [28,29]] or moderately depressed [n=17; IDS-SR
score 26–38 [28,29]] with a mean IDS-SR score of 17.0
(SD=10.7). Only two bipolar patients (3.1%) were medication-
free; the majority of all other patients used 1 (52.3%, n=34)
psychotropic drug. Unfortunately, no complete information on
dosage of psychotropic medication is available.
Table 5. Associations between HPA categories and depressive symptoms.
CAR (n=61) Diurnal (n=62) Evening (n=58) DST (n=56)
Beta
{ [95%CI] Beta
{ [95%CI] Beta
{ [95%CI] Beta
{ [95%CI]
IDS-SR 20.02 [20.05; 0.02] 0.39 [0.02; 0.77] 20.01 [20.09; 0.06] 20.03[20.12; 0.06]
{All values are regression coefficients (beta’s) indicating the mean change in IDS-SR total score, divided by 13, associated with an increase of 1 unit HPA value.
Higher values indicate worse performance.
Betas are corrected for age, gender, education and IQ.
IDS-SR=Inventory of Depressive Symptomatology-self rating; CAR=cortisol awakening response; Diurnal=diurnal slope; evening=mean evening cortisol level;
DST=cortisol suppression on the dexamethasone suppression test; 95%CI=95% confidence interval.
doi:10.1371/journal.pone.0037119.t005
Table 6. The explaining effect of diurnal slope (n=62) on the
associations between depressive symptoms and cognitive
performance (only beta’s presented).
Beta
{ [95%CI] Beta
£ [95%CI] % change [95% CI]
Speed 0.47 [0.14; 0.79] 0.50 [0.16; 0.84] 6.76 [29.35; 65.58]
Process 0.26 [20.10; 0.61] 0.26 [20.11; 0.63] 1.21 [240.36; 40.16]
Attention 0.26 [0.04; 0.49] 0.29 [0.06; 0.53] 12.22 [21.49; 59.68]
Mean 0.21 [0.04; 0.37] 0.24 [0.07; 0.41] 16.71 [21.90; 68.14]
For all measures: Beta’s are corrected for age, gender, education and IQ.
Higher values indicate worse performance.
95%CI: 95% confidence interval.
{Regression coefficients (beta’s) indicating the mean change in cognitive
performance, associated with an increase of 13 points IDS-SR score.
£Regression coefficients (beta’s), after inclusion of diurnal slope in the model.
Diurnal=diurnal slope; Speed=psychomotor speed; Process=speed of
information processing; Attention=attentional switching; Mean=mean z-score
of all 6 cognitive domains; % change=difference score divided by startvalue
{;
95%CI=95% confidence interval.
doi:10.1371/journal.pone.0037119.t006
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cognitive functioning
Evaluation within subgroups of availability of the respective
HPA axis indicator showed that depressive symptoms were
modestly associated with psychomotor speed, attentional switching
and the mean cognitive score; effect sizes were in the range of 0.19
and 0.50 (see Table 3). These effect sizes were comparable with
our prior study in the total sample [26].
Association between HPA axis activity and cognitive
functioning
Table 4 demonstrates that changes in HPA axis activity were
not associated with any of the cognitive domains.
Association between HPA axis activity and depressive
symptoms
From Table 5 it can be seen that depressive symptoms were
modestly associated with attenuation in diurnal slope value only.
The potentially explaining role of HPA axis activity in the
association between depressive symptoms and cognitive
functioning
Table 6 presents the results of the analyses on the explanation of
the association of depressive symptoms with cognition by diurnal
slope, since this HPA axis indicator was the only one that was
shown to be associated with either cognitive functioning or
depressive symptoms (Tables 4 and 5). After addition of this HPA
axis indicator to the independent variables as a possibly explaining
factor, only minute and statistically non-significant mediated
effects were found in the percentage change-range of 1% to 17%
with large 95%-confidence intervals, all including zero.
Discussion
In our previous study (van der Werf-Eldering et al., 2010) we
showed that cognitive dysfunction is associated with depressive
symptoms in bipolar disorder. The aim of the current study was to
investigate a potential mechanism explaining this relationship.
Variation in HPA-axis activity, and therewith altered circulating
cortisol levels, might play a role as disturbances of the HPA axis
have been reported in bipolar disorder and depression [8–13,15]
and to be associated with cognitive disturbances in both healthy
subjects and subjects with mood disorders [18–20,23–25].
In the present study we assessed the magnitude by which the
association between depressive symptoms and cognitive function is
explained by HPA-indicators. The amount of explanation
appeared negligible and therefore we could not confirm the
hypothesis that the relationship between depressive symptoms and
cognitive functioning is mediated by HPA-axis activity.
This led us to reevaluate the literature on findings supporting
the hypothesis that there is a relationship between HPA-axis
functioning and cognition, since negative effects of glucocorticoids
on hippocampal neurons have been described in both animal
experiments and humans in relation to depression [43]. Although
hippocampal atrophy is found in both hypercortisolemic patients
suffering from Cushing’s disease [44] and in patients with major
depressive disorder [45], there is so far no evidence that this
explains disturbances in cognitive functioning in depression. Stress
has an effect on all memory related processes – encoding,
consolidation, retrieval, and re-consolidation [46]. However, we
did not find an association between depressive symptoms and the
cognitive domain memory. The association between depression
and cognition we found was with attentional switching and
psychomotor speed. The relation between cortisol and these two
domains remains unclear and has to our knowledge not specifically
been studied in relation to the HPA-axis. In a study by Comijs et
al. [47] the association found between levels of cortisol and
domains of memory and information processing speed were
independently from depression status, also suggesting that
although both cognitive dysfunction and HPA-axis dysregulation
co-occur in depression, the mechanism behind cognitive dysfunc-
tion might be a different one than HPA-axis dysregulation.
This study is, to our knowledge, the first investigating the
relationship between HPA-axis activity and cognitive functioning
in bipolar patients. We consequently compared our results with
three previous studies in unipolar rather than bipolar depression
keeping this limitation in mind. In unipolar depressed patients
Egeland et al. [24] found an association between high morning
cortisol levels and the cognitive domains executive functioning and
post-encoding memory, both retrieval and storage. The 26
subjects were on average severely depressed (mean Hamilton
Depression Rating Scale scores 21.462.9) which is in contrast with
our group of 65 mildly depressed subjects (mean IDS-SR
17.0610.7), closer to non-depressed subjects. Reppermund et al.
[23] and Zobel [25] studied the relationship between the HPA
axis, cognitive functioning and depression in a different way: by
repeated assessments and in relation with treatment outcome.
Reppermund et al. [23] reported a dissociation between depressive
symptomatology and HPA-axis functioning in their impact on
cognitive functioning. Zobel et al. [25] found that the reduction of
the HPA axis activity was related with improvement in working
memory, while this was independent of a reduction in depression
severity. It is important to realize that the core hypotheses of the
study of Zobel et al. was to postulate specific relationships between
changes in three formulated domains of correlates of depressive
disorders, to mention the severity of depressive symptoms,
cognitive measures and HPA responsivity to the DEX/CRH test
using repeated measurements over a period of 4 weeks; our study
was pointed towards another question, investigating the potential
role of HPA axis dysfunction in order to explain the relationship
between cognitive dysfunction and depressive symptoms. Besides
different diagnoses (major depressive disorder versus bipolar
disorder), the inclusion criteria with regard to the severity of
depressive symptoms was different; Zobel et al. accepted only
moderate-severely depressed inpatients (Hamilton Rating Scale for
Depression with 17 items (HAMD17) above 18, comparable with
IDS-SR score above 36) with the average of HAMD17 of 25
(comparable with IDS-SR score above 48). Our study excluded
patients with IDS-SR score above 39. It is likely to assume that the
higher the level of depressive symptoms, the more fluctuations in
HPA axis functioning could be observed. Zobel et al. also made
use of the DEX/CRH test, known to be more sensitive than the
dexametasone suppression test. However, our cognitive test
battery included a variety of tests, leading to an average score of
each domain, probably reflecting a more realistic picture of
cognitive functioning instead of calculating with the outcome
scores of one single test with the risk of learning effect by repeated
measurements, as was done in the study of Zobel et al.
To appreciate our findings some strengths and limitations have
to be mentioned. With respect to the reliability of our data
assessment, the cognitive test battery used in our study covers all
relevant cognitive domains with regard to bipolar disorder, but by
averaging different tasks within the corresponding domains, it
reduces multiple comparisons for data analysis and avoids
disproportionate emphasis of single test results [48]. In this
manner we expanded the number of domains that have been
evaluated in depressed bipolar patients [2]. Regarding the HPA
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assessing the HPA-axis responsiveness (DST and CAR) and
cortisol levels (diurnal slope and evening cortisol levels) as used in
the NESDA study [11,14,37]. However, despite the overall quality
of the HPA-indicators, the reliability of the DST is limited, due to
the fact that only one sample was taken at awakening the morning
after dexamethasone intake without later samples. In this manner
the suppression of the rise of cortisol after awakening may have
been missed. Also, the time lapse between neuropsychological
assessment and saliva sampling in our study with a median of 6
days could be a possible limitation. As the HPA-system is very
sensitive for stressful events it is possible that in some cases the
HPA-axis indicators might have changed compared to the
moment of neuropsychological testing. Also, due to lack of
available data, the effect of smoking and clinical determinants (e.g.
duration of illness) regarding HPA-axis indicators could not be
evaluated. Another potential limitation is the fact that exclusion of
possible dementia was made clinically without formal assessments.
In addition, the sample size of our study counted a total number of
65 bipolar patients. Although this number is limited regarding
evaluation of more detailed analyses, it seemed to be sufficient to
answer the primary question. The percentages explained were
mostly close to zero and it is in our view unlikely that they would
become statistically significant if we had included a larger sample.
Finally, our study was cross-sectional which leaves the temporal
order of events unspecified. Consequently, we could not distin-
guish between on the one hand a model in which HPA axis
disturbances causes depressive symptoms which in turn cause
cognitive problems (through another mechanism), and on the
other hand a model in which HPA axis disturbances cause both
depressive symptoms and cognitive deficits, i.e. they form
a common cause.
In conclusion, in line with previous studies in unipolar
depression, our results indicate that the significant association
between severity of depressive symptoms and cognitive functioning
in bipolar patients cannot be explained by changes in HPA-axis
activity. As our study is the first one in this field specific for bipolar
patients, other studies are needed to evaluate other factors that
might explain the relationship between depressive symptoms and
cognitive functioning. Future studies on mediation of the relation-
ship between cognitive dysfunction and mood symptoms should
preferably be longitudinal. In addition, more knowledge is needed
and recent research in psychiatric disorders hypothesizes for
example about inefficient glucocorticoid signaling at different
levels [21,49], but also about other divergent kinds of knowledge,
like a link with inflammatory processes [50], with sleep [51], or
with cerebrovascular and degenerative changes [52].
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